Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transdermal patch Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

NCT02968719
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E
Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Heart Rate Variability Biofeedback for Smoking Cessation

NCT03972137
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Cognitive-Behavioral Smoking Cessation, Heart Rate Variability Biofeedback (HRVB), Transdermal Nicotine patch
Behavioral · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 22, 2026, 6:40 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Smoking Cessation Intervention

NCT03072511
View directory record Official record
Conditions
Smoking Cessation
Interventions
Spotlight on Smoke-Free Living: Mindsets and Decisions, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fentanyl Patch Pharmacokinetics in Healthy Adults

NCT02531971
View directory record Official record
Conditions
Peer Review, Research
Interventions
Intravenous fentanyl citrate, Duragesic®, Mylan generic fentanyl
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 22, 2026, 6:40 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers

NCT01907594
View directory record Official record
Conditions
Cigarette Smoking
Interventions
D-cycloserine, Nicotine Replacement Therapy (patch), Smoking Cue Exposure, Progressive Muscle Relaxation, Placebo
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Investigation of Female Reproductive Hormone Dynamics During Adolescence

NCT02486757
View directory record Official record
Conditions
Menstruation Disturbances
Interventions
micronized progesterone, transdermal estradiol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 16 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 22, 2026, 6:40 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

NCT06686537
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Estradiol Patches
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 6:40 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

NCT02697227
View directory record Official record
Conditions
Cigarette Smoker, Tobacco Use Disorder
Interventions
Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
Up to 85 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

NCT02338648
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

NCT01381016
View directory record Official record
Conditions
Obesity, Infertility
Interventions
Estradiol, Gonadotropin-releasing hormone (GnRH), Progesterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Results available

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

NCT00541346
View directory record Official record
Conditions
Autism, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
6 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Bioavailability of Diclofenac Dermal Products

NCT03145259
View directory record Official record
Conditions
Bioavailability
Interventions
Diclofenac Epolamine Patch, diclofenac sodium solution
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD

NCT02511782
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
D-SQUAME Skin Sampling Discs
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 30 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch, Blood Flow and Oxidative Stress Study

NCT00954096
View directory record Official record
Conditions
Healthy
Interventions
transdermal nicotine patch (7mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2009 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121
View directory record Official record
Conditions
Contraception
Interventions
MR-100A-01
Drug
Lead sponsor
Mylan Technologies Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 2Phase 3 Interventional

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

NCT07739589
View directory record Official record
Conditions
Residual Drug Amount of EE and LNG
Interventions
Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

NCT00724815
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Results available

Pharmacogenetics of Nicotine Addiction Treatment

NCT01314001
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Varenicline, Placebo, Transdermal Nicotine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 22, 2026, 6:40 AM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 22, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms

NCT00578669
View directory record Official record
Conditions
Major Depressive Disorder, Nicotine Dependence, Depression
Interventions
Fluoxetine, Dextrose
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 22, 2026, 6:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

NCT05377905
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
Interventions
Microneedle Array Doxorubicin (MNA-D)
Drug
Lead sponsor
Falo, Louis, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 6:40 AM EDT